

# EVERY MAN IS DIFFERENT. EVERY PROSTATE CANCER IS UNIQUE.

Are you making the most informed treatment decision?

KNOW THE FACTS BEFORE YOU BEGIN TREATMENT

OVER **50%** OF NEWLY-DIAGNOSED MEN HAVE **LOW-RISK PROSTATE CANCER** THAT IS UNLIKELY TO SPREAD.




YET A MAJORITY OF THEM RECEIVE IMMEDIATE AGGRESSIVE TREATMENT which may lead to impotence and incontinence.


## MISCONCEPTIONS WOMEN AND MEN HAVE ABOUT PROSTATE CANCER

THAT PROSTATE CANCER IS ALWAYS...


HIGH RISK



LIFE THREATENING



BEST TREATED IMMEDIATELY



Not knowing which treatment to choose with confidence and potential side effects rank as men's top concerns.

## A LESS AGGRESSIVE APPROACH MIGHT BE THE BEST CHOICE FOR YOU

# ACTIVE SURVEILLANCE

This is a program that regularly monitors cancer for progression that allows some patients to avoid immediate treatment and the accompanying side effects.


ASK YOUR DOCTOR ABOUT A GENOMIC TEST  
*to help you make the right decision.*

YOUR PROSTATE  
YOUR DECISION

VISIT [YourProstateYourDecision.com](http://YourProstateYourDecision.com) TO FIND OUT MORE.

## ACTIVE SURVEILLANCE OR IMMEDIATE TREATMENT?

The Oncotype DX® Prostate Cancer Assay helps you and your doctor choose with confidence.



PSA 6.2  
Gleason Score 6  
Oncotype DX® GPS 11

Identified for  
**ACTIVE SURVEILLANCE**

The Oncotype DX Prostate Cancer Assay provides precise and more accurate information about your cancer, so you and your doctor can confidently choose an individualized treatment plan that's right for you.

For more information, visit  
[OncotypeDX.com/prostate](http://OncotypeDX.com/prostate)

Genomic Health and Oncotype DX are registered trademarks of Genomic Health, Inc.  
© 2015 Genomic Health, Inc. All rights reserved. GHI40129\_0615

**Genomic Health**

**oncotype DX**  
breast | colon | prostate